Irish medical device company Medtronic has launched Solitaire X, a revascularisation device intended to treat patients with acute ischemic stroke, in the US.
The device can be used to mechanically remove blood clots from blocked vessels in the brain. This helps restore blood flow in acute ischemic stroke patients with large vessel occlusion.
Stroke, which causes approximately six million deaths annually, is considered as the second leading cause of death worldwide. The condition is also the leading cause of serious, long-term disability in the US. A stroke occurs every 40 seconds in America, and is responsible for a death every four minutes, affecting around 795,000 people a year.
Solitaire X is the company’s fourth generation device. It is equipped with an optimised delivery system to enhance efficiency along with the technical features of its predecessor revascularisation devices.
Medtronic Neurovascular business vice-president and general manager Stacey Pugh said: “Our commitment to enable physicians to improve outcomes for stroke patients worldwide will always be our motivation.
“The net result of that commitment is the launch of a 4th generation device – Solitaire X – which marks ten years of innovation in stroke therapy.”
The company has also launched a 160cm microcatheter, dubbed Phenom 21 Catheter, for the delivery of all sizes of the latest revascularisation device.
In combination with the microcatheter, Solitaire X is expected to offer a low clot crossing profile and enable smooth delivery to occlusions in distal vessels as small as 2mm.
UCLA professor of radiology and neurosurgery Dr Reza Jahan said: “Medtronic continues to deliver technological innovations to advance stroke treatment. As a long-time Solitaire user, I am impressed with the ease of the Solitaire X delivery.
“I find that Solitaire X 6×40 device combined with Phenom 21 catheter provides smooth navigation especially when working with complicated anatomy.”